Multisystem Inflammatory Syndrome In Children (MIS-C)

Published at: 12.01.2022 17:29

blog-post-img

What is MIS in childer? For more than a year, we’ve had COVID-19 as our companion, friend, enemy, and accomplice in our everyday routines. We’ve already suffered several waves, went through a few new variants and there are certainly more to come. As the pandemic is a present and possible future, we can expect anything to happen and hope for good news.

In general, the children often are asymptomatic or develop mild symptoms, and are unlikely to get hospitalized with severe COVID-19.

But it appears that’s not 100 % true and it’s about to change because COVID-19 mutates rapidly all the time. So, do we have to worry, given the circumstance our children aren’t used to all restrictions and the playground is permanently overcrowded?

Recently, scientists are pointing at a condition, called multisystem inflammatory syndrome in children (MIS-C). It appears we’re facing a multiple organ disease in children, a rare but serious complication associated with COVID-19. Children with MIS-C either had the SARS-CoV-2 virus or had been around someone sick and certainly required intensive care.

The National Institute of Allergy and Infectious Diseases (NIAID) launched a huge study to evaluate both short and long-term consequences of SARS-CoV-2 infection in children, including MIS-C. It’s called the Collaboration to Assess Risk and Identify Long-term Outcomes for Children with COVID (CARING for Children with COVID). However, the results will be available in the middle of 2022. As it occurs, children represent 13 % of the total COVID-19 cases in the U.S. Since April 15, over 3.63 million children have tested positive for COVID-19 since the onset of the pandemic. 

The study covered a 2-year period and enrolls 250 participants less than 21 years of age. The program develops new research protocols for 3 clinical networks with leading children’s medical centers in the U.S. and Canada. They focus on:

  • Long-term outcomes after the MIS-C, stressing cardiovascular complications and gathering data, based on all aspects of childhood and adolescent health in affected participants.  A safety profile for the treatment of  MIS-C with medicines that have shown promise in adults with COVID-19. Immunologic mechanisms and characteristics associated with different forms of MIS-C and COVID-19 in children.

While we’re still expecting the estimated completion date, CDC initiated another survey, collecting data from March 2020 to January 2021. It’s published in Jama Pediatrics Journal and incorporated 1733 patients with MIS-C. The majority required intensive care as identified with predominantly gastrointestinal, mucocutaneous, and cardiovascular manifestations. Most of the participants were younger than 15 but the study included up to age 20. 

While we’re still expecting the estimated completion date, CDC initiated another survey, collecting data from March 2020 to January 2021. The majority required intensive care as identified with predominantly gastrointestinal, mucocutaneous, and cardiovascular manifestations. Most of the participants were younger than 15 but the study included up to age 20. 

Researchers aimed to measure the clinical characteristics and geographic and temporal distribution of MIS-C in the U.S.

Due to delayed immune response, the MIS-C occurs 2 to 5 weeks after COVID-19 peaks and follows the spread of initial infections from urban to rural areas. The scientist also stressed a better diagnostic for MIS-C patients,  no matter the lack of prior coronavirus symptoms. 

  • - 1567 patients (90.4%) had illness manifestation involving at least 4 organ systems.
  • - The most common symptoms were abdominal pain, vomiting, diarrhea, and red skin rash. 
  • - Almost one-third had heart inflammation or other cardiac involvement. 
  • - A higher number of patients aged 18 to 20 years had myocarditis, pneumonia, and ARDS.
  • - Patients of group 0 – 4 age were less likely to require medical care, compared to the older ones.

When it comes to MIS-C, disturbing news is all over the web.

BBC states on a breathtaking interview for the death of 1-year Lucas, diagnosed with MIS-C. He’s one of the 1300 babies in Brazil to die of MIS-C associated with COVID-19. It’s really sad to see a young life go away in just 2 months because the doctor refused to do a COVID-19 test.

In Turkey, medical workers noticed the age demographic suddenly dropped down compared to what it was before a few months. According to data collected from 5 different countries, children of the age of 0 to 9 now need to be considered a high-risk group.

However, children’s vaccines are still not an option and both Pfizer and Moderna are in a process of clinical trials. There is yet no convincing evidence that COVID-19 vaccines prevent 100 % of the transmission of the virus, according to the world health organization chief scientist. It’s a fact that people are still catching COVID-19 even after taking the vaccine. So, is there a point in vaccinating kids and putting their lives in danger, in order to dismiss the low possibility of suffering from MIS-C? What’s more important: which one involves a higher risk – children vaccination or MIS-C itself? Before all of that necessary information becomes absolutely clear, we’d better keep our options open. Anyway, hoping for quick answers and a brighter future for us and our children is always helpful.

Author


Read more articles


blog-post-img

What is black tea good for? Is it healthy?

Read
blog-post-img

Innovating regardless what it does do to nature?

Read
blog-post-img

What Does A Magnesium Supplement Do?

Read
blog-post-img

The World After Coronavirus. The Future of Education.

Read